Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib

Clinical Pharmacokinetics

Volumn 43, Issue 5, 2004, Pages 341-348

  Scott, Graham ^a   Reynolds, Christine Vinluan ^b   Milosavljev, Slavica ^b   Langholff, Wayne ^b   Shenouda, Magdy ^c   Rordorj, Christiane ^b  

^a Horsham Research Centre   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; LUMIRACOXIB; MAGNESIUM HYDROXIDE; OMEPRAZOLE;

ABDOMINAL PAIN; ADULT; AGED; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARITHMETIC; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HUMAN; MALE; NECK PAIN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TENSION HEADACHE;

ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; ANTACIDS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYCLOOXYGENASE 2; DICLOFENAC; DRUG COMBINATIONS; ENZYME INHIBITORS; FEMALE; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; ISOENZYMES; MAGNESIUM HYDROXIDE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OMEPRAZOLE; ORGANIC CHEMICALS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 2042481373     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443050-00006     Document Type: Article

References (29)

1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340 (24): 1888-900
2. Guarner F. Prescribing nonsteroidal anti-inflammatory drugs together with antisecretory agents is safe but may be useless. Gastroenterology 1996; 111: 1145-7
3. AstraZeneca. Prilosec® (omeprazole) [package insert]. Wilmington (DE): AstraZeneca, 2003
4. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002 Dec 26; 347 (26): 2104-10
5. Lanas A, Rodrigo L, Marquez JL, et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol 2003 Jul; 38 (7): 693-700
6. Maalox® (magnesium hydroxide - aluminum hydroxide antacid) [package insert]. Parsippany (NJ): Novartis Consumer Health, 2003
7. Andersson T, Bredberg E, Lagerstrom PO, et al. Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. Eur J Clin Pharmacol 1998; 54 (5): 399-404
8. Neuvonen PJ. The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac. Br J Clin Pharmacol 1991; 31 (3): 263-6
9. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-8
10. Goldstein JL, Agrawal NM, Silverstein F, et al. Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal events in osteoarthritis and rheumatoid arthritis patients as compared to NSAIDs [abstract]. Gastroenterology 1999; 116 (4): G0758
11. Sigthorsson G, Crane R, Simon T, et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 2000; 47 (4): 527-32
12. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282 (20): 1921-8
13. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282 (20): 1929-33
14. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000; 43 (2): 370-7
15. Rordorf C, Kellet N, Mair S, et al. Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 2003; 18: 1-10
16. Atherton C, Jones J, McKaig B, et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel COX-2 selective inhibitor: a preliminary integrated study. Clin Gastroenterol Hepatol 2004; 2 (2): 113-20
17. Scott G, Rordorf C, Blood P, et al. Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects [abstract]. Ann Rheum Dis 2002; 61: 242
18. Mangold JB, Gu H, Rodriguez LC, et al. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects [abstract]. Drug Metab Rev 2002; 34 (1 Suppl.): 141
19. Data on file, Novartis Pharmaceuticals Corporation, East Hanover, (NJ), USA, 2000.
20. Marshall PJ, Berry JC, Wasvary J, et al. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2 [abstract]. Ann Rheum Dis 2002; 61: 259
21. Scott G, Rordorf C, Milosavljev S, et al. Multiple-dose lumiracoxib shows rapid absorption and COX-2 selectivity without accumulation in patients with rheumatoid arthritis. In: Tulunay FC, Orme M, editors. European collaboration: towards drug development and rational drug therapy [abstract P-197]. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. Berlin: Springer-Verlag, 2003: 124
22. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277 (11): 925-6
23. Wilde MI, McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994; 48(1): 91-132
24. Data on file, Novartis Pharma AG, Basel, Switzerland, 2001.
25. Center for Drug Evaluation and Research. Bioavailability and bioequivalence studies for orally administered drug products: general considerations [guidance for industry]. Rockville (MD): Food and Drug Administration, Center for Drug Evaluation and Research, 2000
26. Wilding I, Connor A, Carpenter P, et al. Lumiracoxib shows similar bioavailability at different sites in the gastrointestinal tract. In: Tulunay FC, Orme M, editors. European collaboration: towards drug development and rational drug therapy [abstract P-196]. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. Berlin: Springer-Verlag, 2003: 123
27. Abelo A, Andersson TB, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28 (8): 966-72
28. Furuta S, Kamada E, Suzuki T, et al. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 2001; 31 (1): 1-10
29. Neuvonen PJ, Kivisto KT. Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids. Eur J Clin Pharmacol 1988; 35 (5): 495-501